AP NEWS

The Global Myelofibrosis Therapeutics Market (2018-2022): Set to Exceed 7% CAGR - ResearchAndMarkets.com

January 23, 2019

DUBLIN--(BUSINESS WIRE)--Jan 23, 2019--The “Global Myelofibrosis Therapeutics Market 2018-2022” report has been added to ResearchAndMarkets.com’s offering.

The myelofibrosis therapeutics market will register a CAGR of more than 7% by 2022.

Myelofibrosis is a Philadelphia chromosome-negative myeloproliferative neoplasm (MPN), a rare mutation. The only FDA approved drug therapy is JAKAVI/JAKAFI (Ruxolitinib). It is a potent oral JAK1/JAK2 inhibitor used for treating the patients with myelofibrosis.

HSCT therapy is also having disadvantages regarding the unavailability of matching donors. Other therapies, including the transfusion and androgen therapy, merely reduce the anemic side effects of myelofibrosis.

Thus, among all treatments available at present, none can be considered as an ideal one that can completely help in eradicating the disease.

Increasing number of companies entering the myelofibrosis segment

Before the launch of JAKAVI/JAKAFI, there were very few companies investing in the R&D of myelofibrosis therapies.

Limited market size as myelofibrosis is a rare disorder

The number of available therapies, including the orphan drugs, for this disorder is very limited. The treatment options employed by physicians are mostly off-label drugs that are meant for the treatment of some other condition or blood transfusion or stem cell transplantation.

Key Players

Bristol-Myers Squibb Celgene Incyte Novartis

Topics Covered

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: RESEARCH METHODOLOGY

PART 04: MARKET LANDSCAPE

PART 05: PIPELINE ANALYSIS

PART 06: MARKET SIZING

PART 07: FIVE FORCES ANALYSIS

PART 08: MARKET SEGMENTATION BY TYPE OF TREATMENT

Comparison by type of treatment Drug therapy - Market size and forecast 2017-2022 Blood transfusion - Market size and forecast 2017-2022 HSCT - Market size and forecast 2017-2022 Androgen Therapy - Market size and forecast 2017-2022 Market opportunity by type of treatment

PART 09: CUSTOMER LANDSCAPE

PART 10: REGIONAL LANDSCAPE

PART 11: DECISION FRAMEWORK

PART 12: DRIVERS AND CHALLENGES

PART 13: MARKET TRENDS

HSCT is the only curative option for myelofibrosis High off-label prescription including hydroxyurea, Immunomodulators, and steroids

PART 14: VENDOR LANDSCAPE

PART 15: VENDOR ANALYSIS

Vendors covered Vendor classification Market positioning of vendors Bristol-Myers Squibb Celgene Incyte Novartis

For more information about this report visit https://www.researchandmarkets.com/research/cpjg4d/the_global?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20190123005657/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Leukemia Drugs,Hematological Drugs

KEYWORD:

INDUSTRY KEYWORD: HEALTH ONCOLOGY PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 01/23/2019 12:26 PM/DISC: 01/23/2019 12:26 PM

http://www.businesswire.com/news/home/20190123005657/en

AP RADIO
Update hourly